Thus, modulating the miR-34a/AXL pathway in RA DCs by using miR-34a inhibitors or AXL agonist could be a feasible therapeutic strategy to restore homoeostasis and promote resolution of RA. Here, AXL is linked to rheumatoid arthritis.